CT1812, a σ2 receptor allosteric antagonist for mild-to-moderate AD treatment [193], has proved to displace toxic AβO from the synaptic receptor, facilitate oligomer clearance into the CSF and restore cognitive function [193,194]. This evidence concerns the gene ABO and Alzheimer disease.